{"id":"W3202237143","doi":"10.1016/j.annonc.2021.08.878","title":"1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Antagonist; Sarcoma; Oncology; Internal medicine; Phases of clinical research; Pharmacology; Chemotherapy; Pathology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005320404,0.001033691,0.001555991,0.0003744808,0.0003742299,0.0007332409,0.0005871964,0.0008666819,0.005819314],"category_scores_gemma":[0.0005122247,0.0005114229,0.0006314336,0.0003242955,0.0006110849,0.0006007356,0.0002969432,0.002876881,0.001744588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006615918,"about_ca_system_score_gemma":0.0009474096,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001270567,"about_ca_topic_score_gemma":0.002738282,"domain_scores_codex":[0.9997711,0.00008782366,0.00001006812,0.00004072403,0.0000238733,0.00006652457],"domain_scores_gemma":[0.9997869,0.00003110203,0.00002574864,0.00002113018,0.00001499591,0.0001201323],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4412044,0.06756195,0.009435628,0.0008952761,0.00114327,0.0007690995,0.0004769498,0.005942032,0.1749725,0.0008331304,0.01631807,0.2804477],"study_design_scores_gemma":[0.3784342,0.5776887,0.01937892,0.0000586703,0.0005004203,0.000720009,0.0001356034,0.002574946,0.008659076,0.0005006494,0.01129791,0.00005084765],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924403,0.001021811,0.0004228392,0.000699026,0.0001256113,0.001065578,0.0008814954,0.0001216912,0.003221584],"genre_scores_gemma":[0.9872265,0.001166233,0.00173233,0.0007808821,0.0001230973,0.001387672,0.002203909,0.00004696322,0.005332352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005819314,"threshold_uncertainty_score":0.01946759,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07771101551057516,"score_gpt":0.4385623339994136,"score_spread":0.3608513184888384,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}